A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

DOI: https://doi.org/10.1038/s41416-019-0452-3

Full-Text   Cite this paper   Add to My Lib

Abstract:

Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy

Full-Text